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Abstract
Background: ADAM17/TACE activity is important during embryonic development. We wished to investigate possible roles
of this metalloprotease, focusing on vascular development.
Methodology/Principal Findings: Mice mutant in the enzymatic activity of ADAM17 were examined at various stages of
embryonic development for vascular pattern and integrity using markers for vessel wall cells. We observed hemorrhage and
edema starting at embryonic day E14.5 and becoming more severe as development proceeded; prior to embryonic day
E14.5, embryos appeared normal. Staining for PECAM-1/CD31 revealed abnormalities in the patterns of branching of the
embryonic vasculature at E14.5.
Conclusions/Significance: These abnormalities preceded association of pericytes or monocyte/macrophage cells with the
affected vessels and, therefore, presumably arise from defects in endothelial function consequent upon failure of ADAM17
to cleave one or more substrates involved in vascular development, such as Notch, Delta, VEGFR2 or JAM-A. Our study
demonstrates a role for ADAM17 in modulating embryonic vessel development and function.
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Introduction
The members of the ADAM (A Disintegrin And Metallo-
protease) family of proteases are metzincin-enzymes that cleave
a variety of substrates including cytokines, proteins of the
extracellular matrix, cell adhesion molecules and growth
factors. ADAM17, also referred to as Tumor necrosis factor
Alpha Converting Enzyme (TACE, CD156b) [1], is the most
studied member of this family and participates in the shedding
of more than 40 different substrates [2–4]. ADAM17 is
expressed in most tissues, where it plays important physiolog-
ical and pathophysiological roles since it has been implicated in
inflammatory disorders, brain pathology and cancer. In
addition, ADAM17 activity appears to be important during
embryonic development since mice lacking ADAM17 activity
die during the late gestational stages or soon after birth [5].
These mice not only present defects in skin, muscle and
neuronal tissues [5] but also exhibit impaired heart and lung
morphogenesis [6,7] that were postulated to be responsible for
the premature mortality. Interestingly, an underdeveloped
pulmonary vascular network was also observed in mice
deficient in ADAM17 activity [7] suggesting a possible
requirement for a fully functional ADAM17 for normal
angiogenesis in embryos. In vitro, potential involvement of
ADAM17 in angiogenesis was recently illustrated in two studies
where knocking down [8] or silencing [9] ADAM17 in human
endothelial cells inhibited cell proliferation and prevented the
formation of capillary networks in three-dimensional matrices
[8]. Given the implication of ADAM17 activity in angiogenesis
in vitro, we sought to address whether a catalytically inactive
form of ADAM17 could impact vessel formation and function
during embryonic development in vivo. We observed vascular
malformations and hemorrhage during embryonic development
of mice homozygous for a mutation inactivating ADAM17, thus
demonstrating a role for this protease in modulating vascular
development.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13433Results
ADAM17 Inactivation Causes Hemorrhaging in
Developing Embryos
Intercrosses among heterozygous Adam17
DZn/+ mice were
conducted to generate homozygous embryos deficient in AD-
AM17 activity. As previously reported [5], we observed an
increased mortality of the Adam17
DZn/DZn embryos at E17.5 (50%
of embryos died, Supplementary Figure S1A) but not at earlier
developmental stages (E11.5 and E14.5). Macroscopic observation
at E14.5 and E17.5 revealed that Adam17
DZn/DZn embryos showed
a tendency to be underweight (Supplementary Figure S1B) and
shorter in length (data not shown) as compared with the Adam17
+/+
and Adam17
DZn//+ fetuses although the differences were not
statistically significant.
A detailed examination of the fetuses revealed that Adam17
DZn/DZn
embryos appeared to develop normally until E11.5 (Figure 1A).
However at E14.5 and E17.5, 50% and 67% of the Adam17
DZn/DZn
embryos, respectively, exhibited internal hemorrhaging (Table 1).
The Adam17
+/+ and Adam17
DZn/+ littermates did not show signs of
bleeding at any developmental stage we studied (Table 1 and
Figure 1). In the Adam17
DZn/DZn embryos bleeding appeared between
E11.5andE14.5andlocalizedprimarilyonthesideoftheheadofthe
embryos and the extent and localization of bleeding progressed with
e m b r y o n i ca g e( F i g u r e1 Ba n d1 C ) .F u r t h e r m o r e ,a tE 1 7 . 5t h e
mutant embryos showed signs of edema on the neck and the upper
back area. We found no hemorrhagic lesions on the yolk sac
vasculature of the Adam17
DZn/DZn embryos (data not shown). Upon
closer examination we observed that at the late developmental stage
(E17.5) blood pooling was accompanied by a loss of the vascular
organization in mutant embryos compared with the heterozygous
and wild-type littermates (Figure 2, compare arrows in D and E
with F). These results suggest a defect in vessel integrity in the
Adam17
DZn/DZn embryos.
Impaired Vascular Patterning in Mutant Embryos
To investigate the potential causes of bleeding in Adam17
DZn/DZn
embryos, we compared the vasculature of wild-type and mutant
embryos as revealed by CD31 (PECAM) immunohistochemistry.
Since the first evidence of hemorrhage was detected at around
E14.5, we compared the whole-mount PECAM-1 (CD31) staining
patterns of wild-type, Adam17
+/DZn and Adam17
DZn/DZn embryos at
this stage (Figure 3 and 4). At this developmental period, there were
no obvious defects in the general morphology of the mutant
embryonic body vasculature compared with that of wild-type
embryos. However, closer examination of the cranial vascular
patterning revealed striking differences between the mutant
embryos and their wild-type or heterozygous counterparts. At this
stage, the large cranial vessels projecting posteriorly over the
midbrain region showed an elaborate but reproducible branching
pattern in heterozygous (Figure 3A, B) or wild-type embryonic
heads (Figure 3C). In contrast, the development of this branched
morphologywasmarkedlydisrupted inthe Adam17
DZn/DZnembryos
(Figure 3D). For example, vessels numbered 1–4 in Figure 3 were
longer and often further elaborated with additional branchinginthe
wild-type embryos in contrast with the corresponding vessels in
Adam17
DZn/DZn embryos. In addition to this stunted vessel
morphology, analysis of the Adam17
DZn/DZn mutant phenotype
revealed abnormal fusion of vessels in 3 out of 4 embryos (Table 2).
This type of inappropriate joining of vessels was not restricted to a
particular branch (Figure 4B and 4D) and was sometimes seen in
multiple branches in the same embryo (Figure 4D). This defect was
not observed in four wild-type embryos examined (Figure 4A, C).
These vascular defects at E14.5 appeared to precede the
hemorrhage and could well be contributory to later defects. The
defects in vascular modeling implicate ADAM17 in this process,
raising the question of potential targets for this cell surface protease.
Discussion
Studies on the embryogenesis of mice deficient in ADAM17
activity reveal that these animals suffer from severe defects in the
maturation and the differentiation of epithelial cells resulting in an
impaired development of intestine, parathyroid, salivary glands
lung and heart [5–7]. We now report that Adam17
DZn/DZn
embryos also present abnormal vascular beds that are probably
responsible for internal hemorrhages appearing around E14.5.
However, the vasculature of Adam17
DZn/+ heterozygous embryos
develops normally, similarly to that of wild-type embryos,
revealing that partial expression of ADAM17 is sufficient to
obtain normal vascular development. We did not find major
alterations in the initial steps of vascular development in
Adam17
DZn/DZn embryos but observed abnormal vessel branching
patterns at the later stages of embryonic development compared
Figure 1. Adam17
DZn/DZn embryos develop internal hemor-




DZn/DZn embryos at E11.5 (A), E14.5 (B) and E17.5 (C); embryos
were unfixed, unstained. Adam17
DZn/DZn embryos exhibited hemor-
rhagic lesions compared with their Adam17
+/+ and Adam17
DZn/+
littermates (see dotted boxes in B and C and higher magnification
views in Figure 2). Hemorrhage was observed in E14.5 embryos and
increased with gestational age. At later stage E17.5, the arrows denote
edema.
doi:10.1371/journal.pone.0013433.g001
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abnormalities, we also observed hemorrhage and edema. These
observations are in accordance with a previous report where the
authors detected a poorly developed capillary network in the lungs
of these embryos [7]. Altogether these results suggest that ADAM17
activity seems not to be required for vasculogenesis or early
angiogenesis but is necessary for proper remodeling of pre-existing
vessels and the establishment of capillary networks. Reduction in
the number of vessel branchpoints and in the capillary density is
often linked with defects in the migratory properties of endothelial
cells. Indeed, a role for ADAM17 in modulating endothelial cell
sprouting and ability to invade was recently suggested in cultured
human endothelial cells in which ADAM17 expression was silenced
by delivery of either siRNA or dominant negative constructs [8,9].
These in vitro data provide an interesting mechanistic hypothesis
for a role of ADAM17 in endothelial sprouting capability that
conforms with our in vivo observations.
The vascular defects we observed were likely intrinsic to the
endothelium. We investigated pericytecoverageof the affectedcranial
vessels by staining for NG2 or a-smooth muscle actin. Neither stain
detected any pericytes associated with the relevant vessels in either
wild-type or mutant embryos although both stains readily detected
pericytes around other vessels in the embryos at the same stage (data
not shown). Therefore, the vascular defects and hemorrhage precede
pericyte coverage of the affected vessels, suggesting that these vascular
defects originate in the endothelium. Consistent with that conclu-
sion, a recent paper, investigating an animal model of pathological
angiogenesis [10] showed a role for ADAM17 in endothelial cells but
not pericytes. Interestingly, in that paper no apparent defects in
developmental angiogenesis were reported suggesting either that the
developmental defects that we report can be overcome in subsequent
development or that additional defects arise from absence of
ADAM17 in other cell types. We did check for the possible involve-
ment of cells of the monocyte/macrophage lineage by staining for
F4/80 but no F4/80-positive cells were present in the region of the
vessels in which we observed vascular defects (data not shown),
arguing against a role for cells of this lineage.
Defects in angiogenesis are often accompanied by hemorrhage
[11]. In normal angiogenesis, hemorrhage is prevented by platelets
and their adhesive function through the von Willebrand factor
receptor, GPIba [12]. Platelets express ADAM17 that mediates
shedding of GPIba and several other platelet receptors after
platelet activation. However, in chimeric mice expressing the
inactive ADAM17 on blood cells only, produced by fetal liver
transplant, the hemostatic function of platelets is unaffected or
even improved as they cannot shed GPIba [13]. Thus the
observed hemorrhaging in the Adam17
DZn/DZn embryos is not
likely to be due to defective platelet function in these animals.a
Although the molecular mechanisms by which ADAM17 affects
vessel development and branching still remain unknown, our data
implicate ADAM17 enzymatic activity and not, as recently
hypothesized, ADAM17 interaction with integrins or other
proteins via its disintegrin domain [8]. In the Adam17
DZn/DZn
model, ADAM17 remains expressed in cells and is structurally
unchanged except that its catalytic domain is genetically
inactivated [5]. Despite the presence of the disintegrin domain,
we detect vascular abnormalities in mutant embryos even though
interactions with integrins could still occur. It is known that
ADAM17 is responsible for the cleavage of the extracellular
domains of numerous proteins that participate in the angiogenic
process. Among these substrates is TNF-a (Tumor Necrosis Factor
Alpha), a pleiotropic pro-inflammatory molecule, which also
modulates angiogenesis. TNF-a was first described as an
antiangiogenic compound causing tumor regression [14] but also
exhibits proangiogenic properties in some in vivo conditions
[15,16]. The growth factor TGF-a (Transforming Growth Factor
Alpha) is an ADAM17 substrate that was implicated in the
epithelial abnormalities of Adam17
DZn/DZn embryos and has also
been shown to promote angiogenesis [17]. However, the vascular
phenotype of Adam17
DZn/DZn embryos’ seems unlikely to be
attributable to a loss of soluble TNF-a or TGF-a; to our
knowledge, defects in embryonic vascularization or a bleeding
phenotype have not been reported in mice expressing a non-
Figure 2. Vascular defects and hemorrhage in Adam17
DZn/DZn
embryos. Higher magnifications of the whole unfixed, unstained
embryosatE14.5(A,B, C)andE17.5(D,E,F)as in Figure 1.Adam17
DZn/DZn
embryos (C, F) exhibited blood pooling (star) and loss of visible vascular
structures (arrowheads); e=ear.
doi:10.1371/journal.pone.0013433.g002






Developmental stage E11.5 E14.5 E17.5 E11.5 E14.5 E17.5 E11.5 E14.5 E17.5
Embryos with hemorrhagic
lesions
0 000 000 34
(% of n) 0% 0% 0% 0% 0% 0% 0% 50% 67%
n 71 05 1 4 1 51 25 6 6
doi:10.1371/journal.pone.0013433.t001
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DZn/DZn vascular phenotype. Whole-mount E14.5 embryos were stained with CD31 (PECAM) antibodies to characterize their
vascular morphology. Panel A shows the vasculature of an intact heterozygous embryo. Boxed area indicates the location of the region shown at
higher magnification in panel B after dissection to allow flat mounting to view the cranial vessels. Similar views from heads of wild-type (C) and
mutant (D) embryos. Wild-type patterning of the branches is severely disrupted in Adam17
DZn/DZn embryonic heads. Vessels numbered 1–4 are
stunted and less branched in the mutant embryos. Although the distance between vessel 2 and the branch leading up to vessels 3 and 4 seems
increased in the mutant head shown (red bar), this distance was variable in wild-type heads. The asterisk marks a vessel damaged during dissection.
Scale bars are 200 mm.
doi:10.1371/journal.pone.0013433.g003
Figure 4. Abnormal fusion of branches in Adam17
DZn/DZn cranial vessels. In addition to the stunted morphology, CD31 staining of E14.5
heads revealed abnormal joining of vessels at various branch points in the mutant embryos (3/4 embryos). Arrows indicate these fused branches in
Adam17
DZn/DZn embryos (B, D) and their absence in the wild-type counterparts (A, C). Scale bars are 200 mm.
doi:10.1371/journal.pone.0013433.g004
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a [20] or TGF-a [21]. However, there are other ADAM17
substrates that are clearly implicated in vascular development and
represent likely candidates for an involvement in the phenotypes
we report here. These include the receptors Notch [22], VEGFR-
2 [23], and JAM-A [24] each of which can act at different levels of
the angiogenic and remodeling processes [25–31].
In conclusion, our data indicate that ADAM17 enzymatic
activity plays crucial roles in endothelial biology and in vascular
development in vivo. Therefore, further investigations of potential
ADAM17 substrates need to be undertaken to determine how






DZn/+ heterozygous mice (C57BL/6J/129Sv background)
were kindly provided by Jacques Peschon, Amgen (Seattle, WA).
The Adam17 gene was mutated by deletion of the zinc-binding




+/+ embryos were pro-
duced by intercrossing Adam17
DZn/+ heterozygous mice on a
C57BL/6J/129Sv background and the resulting littermates were
used foranalysis.Day0.5ofpregnancy(E0.5)wasdefined astheday
when a vaginal plug was observed. Animal protocols were approved
by the Animal Care and Use Committee of the Immune Disease
Institute (IDI4M0109/HMS04564). The Immune Disease Insti-
tute’s Animal Care Management Program is accredited by the
American Association for the Accreditation of Laboratory Animal
Care International and meets National Institutes of Health
standards. The Institution also accepts as mandatory the PHS
Policy on Humane Care and Use of Laboratory Animals by
Awardee Institutions and NIH Principles for the Utilization and
Care of Vertebrate Animals Used in Testing, Research, and
Training. An approved Assurance of Compliance is on file with the
Office of Laboratory Animal Welfare. The Immune Disease
Institute’s assurance number is A3251.
Adam17
DZn/DZn Embryo Genotyping
Genotyping was performed by PCR using genomic DNA
extracted from paw tissue. Primers used were: Adam17
+ fwd 59-
CACGGGTAGCCAACGCTATGT-39 and rev 59-GCCCTGA-
ATGAACTGCAGGACC-39 ; Adam17
DZn fwd 59-CTTATTAT-
TCTCGTGGTCACCGCT-39 and rev 59-GAAGCTGACCT-
GGTTACAACTCATG-39.
Body Weight Determination and Microscopy of Unfixed
Embryos
Embryos were harvested from pregnant females at indicated
time points and individually placed on a clean container for weight
determination. The excess of fluid was removed by quick wicking
on a gauze pad prior to weighing. Embryos were then observed
and photographed under a Zeiss Stemi 2000 stereomicroscope.
Immunohistochemistry
E14.5 embryos were fixed in methanol/DMSO (4:1) at 4uC
overnight. Following fixation, embryos were stored in 100%
methanol at 235uC until further processing. The remaining
staining procedure was done at room temperature unless indicated
otherwise. For immunohistochemistry, endogenous peroxidase
activity was quenched by incubating embryos with 2% hydrogen
peroxide (H2O2) in methanol/DMSO (4:1) for 4 hours. After the
H2O2 treatment, embryos were washed in 75%, 50%, 25%
methanol 15 minutes each. Washes with the methanol series were
followed by three 15-minute rinses and an overnight incubation in
PBS (without Ca/Mg). Embryos were then blocked in 10%
normal goat serum (NGS) in PBS containing 0.1% TritonX-100
(PBST) for 2 hours. Blocked embryos were incubated over-
night with primary rat antibody against CD31 (PECAM clone
MEC13.3, BD Biosciences, San Jose, CA) diluted 1:100 in
blocking solution. Primary antibody incubation was followed by
6 one hour and one overnight washes in PBST. The overnight
wash was then replaced with horseradish peroxidase (HRP)-
conjugated anti-rat secondary antibody (Jackson ImmunoRe-
search, West Grove, PA) diluted 1:50 in blocking solution.
Embryos were incubated with the secondary antibody for two
days, washed 6 times one hour each and overnight with PBST.
HRP signal was developed with a DAB substrate kit (Vector Labs,
Burlingame, CA) according to the manufacturer’s instructions,
except that PBST was substituted for the buffer provided.
Developed embryos were post-fixed in 4% paraformaldeyde in
PBS overnight at 4uC, washed 3 times with PBS and cleared by
incubating in 50%, followed by 80% glycerol in PBS overnight at
4uC. Heads of stained embryos were dissected with electrolytically
sharpened tungsten needles and mounted in 80% glycerol. Digital
images of mounted heads were captured either with Openlab
software using a Zeiss Axiophot microscope fitted with a Retiga
Exi camera or with Spot software using a Zeiss Stemi 2000-C
microscope fitted with a SpotRT Slider camera. Fluorescent
staining of embryos was carried out as described above with some
modifications. The NG2 antibody (Abcam, Cambridge MA) and
PECAM antibody (clone MEC13.3, BD Biosciences, San Jose,
CA) were diluted 1:100 for the whole mount stains. The H2O2
treatment step was omitted and a fluorescein-conjugated second-
ary antibody (Invitrogen-Molecular Probes, Carlsbad, CA) was
substituted for the HRP-conjugated anti-rat secondary antibody.
After the secondary antibody incubation, the fluorescently labeled
embryos were washed and incubated in mounting medium (CFM-
1 Plus mounting medium, Electron Microscopy Sciences, Hatfield,
PA) overnight at 4uC without post-fixation for dissections and
mounting.
Table 2. Descriptive Summary of the Adam17




1 One main branch point, with each vessel containing a single minor branch
(4/4 embryos)
One main branch point, stunted vessel (4/4 embryos), minor
branches absent (2/4 embryos)
2 Well-developed vessel with at least 1 branch point (4/4 embryos) Stunted, non-branched (3/4 embryos), absent (1/4 embryos)
3 Well-developed (4/4 embryos) and branched (3/4 embryos) Severely stunted (1/4 embryos) or absent (3/4 embryos)
4 Present (4/4 embryos), well-developed and branched (1/4 embryo) Stunted (2/4 embryos) or absent (2/4 embryos)
doi:10.1371/journal.pone.0013433.t002
ADAM17 in Vascular Development
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E14.5 wild-type embryos were fixed with 4% paraformaldehyde
overnight. Embryos were washed with PBS (without Ca/Mg) and
stored in 70% ethanol until processed for sectioning. Paraffin-
embedded sections were de-waxed into water and heat-mediated
antigen retrieval was performed using Retrievagen A kit (BD
Biosciences, Franklin Lakes, NJ). Sections were blocked with 20%
normal goat serum, 1% fish oil in PBT and for 2 hours at room
temperature. Primary rabbit anti-PECAM (Abcam, Cambridge,
MA) and rat anti-F4/80 (AbD Serotec, Raleigh, NC) antibodies
diluted in 4% normal goat serum/PBT were incubated with the
sections overnight at room temperature. Following washes with
PBS, sections were incubated with fluorescent conjugated
secondary antibodies (Invitrogen-Molecular Probes, Carlsbad,
CA). After 6 washes with PBS, sections were mounted in CFM-
1 Plus mounting medium (Electron Microscopy Sciences, Hatfield,
PA) and imaged with a Zeiss Axiophot microscope.
Statistics
Values are expressed as mean 6 SEM. The statistical
significance was assayed using the one-way ANOVA analysis of
variance followed by Boneferroni’s multiple comparisons test. A p
value,0.05 was considered statistically significant.
Supporting Information
Figure S1 Genotyping and weight of progeny derived from
Adam17
DZn/+ intercrosses. A, The number of viable embryos of
each genotype is listed and the number of additional dead fetuses is
indicated in parentheses. B, The weights of the embryos of each
genotype were measured at E14.5 and E17.5; no statistical
differences were observed among the different genotypes. Values
are represented as mean 6 SEM.
Found at: doi:10.1371/journal.pone.0013433.s001 (2.23 MB EPS)
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